“Shift Toward Non-invasive Solutions”
The shift toward non-invasive solutions in the VEGF-B inhibitors market is becoming more noticeable as patients increasingly opt for procedures that involve less risk and faster recovery times. Endoscopic procedures and gastric balloons are gaining popularity due to their minimally invasive nature, offering effective weight loss results with no need for surgical incisions. These methods are seen as appealing alternatives to traditional bariatric surgeries like gastric bypass or sleeve gastrectomy, which involve more complex operations and longer recovery periods.
Non-surgical options are often associated with lower complication rates, fewer hospital stays, and quicker returns to normal activities. This trend reflects a growing preference for treatments that prioritize convenience and safety, particularly for patients hesitant about undergoing more invasive procedures. As awareness about these options spreads, more individuals are choosing non-invasive treatments to manage obesity effectively.
